Alpha9 nicotinic acetylcholine receptors and the treatment of pain

Autores
McIntosh, J. Michael; Absalom, Nathan; Chebib, Mary; Elgoyhen, Ana Belen; Vincler, Michelle
Año de publicación
2009
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Chronic pain is a vexing worldwide problem that causes substantial disability and consumes significant medical resources. Although there are numerous analgesic medications, these work through a small set of molecular mechanisms. Even when these medications are used in combination, substantial amounts of pain often remain. It is therefore highly desirable to develop treatments that work through distinct mechanisms of action. While agonists of nicotinic acetylcholine receptors (nAChRs) have been intensively studied, new data suggest a role for selective antagonists of nAChRs. α-Conotoxins are small peptides used offensively by carnivorous marine snails known as Conus. A subset of these peptides known as α-conotoxins RgIA and Vc1.1 produces both acute and long lasting analgesia. In addition, these peptides appear to accelerate the recovery of function after nerve injury, possibly through immune mediated mechanisms. Pharmacological analysis indicates that RgIA and Vc1.1 are selective antagonists of α9α10 nAChRs. A recent study also reported that these α9α10 antagonists are also potent GABA-B agonists. In the current study, we were unable to detect RgIA or Vc1.1 binding to or action on cloned GABA-B receptors expressed in HEK cells or Xenopus oocytes. We review the background, findings and implications of use of compounds that act on α9* nAChRs.11* indicates the possible presence of additional subunits.
Fil: McIntosh, J. Michael. University of Utah; Estados Unidos
Fil: Absalom, Nathan. The University of Sydney; Australia
Fil: Chebib, Mary. The University of Sydney; Australia
Fil: Elgoyhen, Ana Belen. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Farmacología; Argentina
Fil: Vincler, Michelle. Wake Forest University Health Sciences; Estados Unidos
Materia
α-Conotoxin Vc1.1
α-Contoxin RgIA
Alpha9 nicotinic
GABA-B
Pain
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/79623

id CONICETDig_85d644871bc2294d63591f234f0dcae5
oai_identifier_str oai:ri.conicet.gov.ar:11336/79623
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Alpha9 nicotinic acetylcholine receptors and the treatment of painMcIntosh, J. MichaelAbsalom, NathanChebib, MaryElgoyhen, Ana BelenVincler, Michelleα-Conotoxin Vc1.1α-Contoxin RgIAAlpha9 nicotinicGABA-BPainhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Chronic pain is a vexing worldwide problem that causes substantial disability and consumes significant medical resources. Although there are numerous analgesic medications, these work through a small set of molecular mechanisms. Even when these medications are used in combination, substantial amounts of pain often remain. It is therefore highly desirable to develop treatments that work through distinct mechanisms of action. While agonists of nicotinic acetylcholine receptors (nAChRs) have been intensively studied, new data suggest a role for selective antagonists of nAChRs. α-Conotoxins are small peptides used offensively by carnivorous marine snails known as Conus. A subset of these peptides known as α-conotoxins RgIA and Vc1.1 produces both acute and long lasting analgesia. In addition, these peptides appear to accelerate the recovery of function after nerve injury, possibly through immune mediated mechanisms. Pharmacological analysis indicates that RgIA and Vc1.1 are selective antagonists of α9α10 nAChRs. A recent study also reported that these α9α10 antagonists are also potent GABA-B agonists. In the current study, we were unable to detect RgIA or Vc1.1 binding to or action on cloned GABA-B receptors expressed in HEK cells or Xenopus oocytes. We review the background, findings and implications of use of compounds that act on α9* nAChRs.11* indicates the possible presence of additional subunits.Fil: McIntosh, J. Michael. University of Utah; Estados UnidosFil: Absalom, Nathan. The University of Sydney; AustraliaFil: Chebib, Mary. The University of Sydney; AustraliaFil: Elgoyhen, Ana Belen. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Farmacología; ArgentinaFil: Vincler, Michelle. Wake Forest University Health Sciences; Estados UnidosPergamon-Elsevier Science Ltd2009-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/79623McIntosh, J. Michael; Absalom, Nathan; Chebib, Mary; Elgoyhen, Ana Belen; Vincler, Michelle; Alpha9 nicotinic acetylcholine receptors and the treatment of pain; Pergamon-Elsevier Science Ltd; Biochemical Pharmacology; 78; 7; 10-2009; 693-7020006-2952CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19477168/info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bcp.2009.05.020info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0006295209004298info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-06-10T09:46:36Zoai:ri.conicet.gov.ar:11336/79623instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-06-10 09:46:37.186CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Alpha9 nicotinic acetylcholine receptors and the treatment of pain
title Alpha9 nicotinic acetylcholine receptors and the treatment of pain
spellingShingle Alpha9 nicotinic acetylcholine receptors and the treatment of pain
McIntosh, J. Michael
α-Conotoxin Vc1.1
α-Contoxin RgIA
Alpha9 nicotinic
GABA-B
Pain
title_short Alpha9 nicotinic acetylcholine receptors and the treatment of pain
title_full Alpha9 nicotinic acetylcholine receptors and the treatment of pain
title_fullStr Alpha9 nicotinic acetylcholine receptors and the treatment of pain
title_full_unstemmed Alpha9 nicotinic acetylcholine receptors and the treatment of pain
title_sort Alpha9 nicotinic acetylcholine receptors and the treatment of pain
dc.creator.none.fl_str_mv McIntosh, J. Michael
Absalom, Nathan
Chebib, Mary
Elgoyhen, Ana Belen
Vincler, Michelle
author McIntosh, J. Michael
author_facet McIntosh, J. Michael
Absalom, Nathan
Chebib, Mary
Elgoyhen, Ana Belen
Vincler, Michelle
author_role author
author2 Absalom, Nathan
Chebib, Mary
Elgoyhen, Ana Belen
Vincler, Michelle
author2_role author
author
author
author
dc.subject.none.fl_str_mv α-Conotoxin Vc1.1
α-Contoxin RgIA
Alpha9 nicotinic
GABA-B
Pain
topic α-Conotoxin Vc1.1
α-Contoxin RgIA
Alpha9 nicotinic
GABA-B
Pain
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Chronic pain is a vexing worldwide problem that causes substantial disability and consumes significant medical resources. Although there are numerous analgesic medications, these work through a small set of molecular mechanisms. Even when these medications are used in combination, substantial amounts of pain often remain. It is therefore highly desirable to develop treatments that work through distinct mechanisms of action. While agonists of nicotinic acetylcholine receptors (nAChRs) have been intensively studied, new data suggest a role for selective antagonists of nAChRs. α-Conotoxins are small peptides used offensively by carnivorous marine snails known as Conus. A subset of these peptides known as α-conotoxins RgIA and Vc1.1 produces both acute and long lasting analgesia. In addition, these peptides appear to accelerate the recovery of function after nerve injury, possibly through immune mediated mechanisms. Pharmacological analysis indicates that RgIA and Vc1.1 are selective antagonists of α9α10 nAChRs. A recent study also reported that these α9α10 antagonists are also potent GABA-B agonists. In the current study, we were unable to detect RgIA or Vc1.1 binding to or action on cloned GABA-B receptors expressed in HEK cells or Xenopus oocytes. We review the background, findings and implications of use of compounds that act on α9* nAChRs.11* indicates the possible presence of additional subunits.
Fil: McIntosh, J. Michael. University of Utah; Estados Unidos
Fil: Absalom, Nathan. The University of Sydney; Australia
Fil: Chebib, Mary. The University of Sydney; Australia
Fil: Elgoyhen, Ana Belen. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Farmacología; Argentina
Fil: Vincler, Michelle. Wake Forest University Health Sciences; Estados Unidos
description Chronic pain is a vexing worldwide problem that causes substantial disability and consumes significant medical resources. Although there are numerous analgesic medications, these work through a small set of molecular mechanisms. Even when these medications are used in combination, substantial amounts of pain often remain. It is therefore highly desirable to develop treatments that work through distinct mechanisms of action. While agonists of nicotinic acetylcholine receptors (nAChRs) have been intensively studied, new data suggest a role for selective antagonists of nAChRs. α-Conotoxins are small peptides used offensively by carnivorous marine snails known as Conus. A subset of these peptides known as α-conotoxins RgIA and Vc1.1 produces both acute and long lasting analgesia. In addition, these peptides appear to accelerate the recovery of function after nerve injury, possibly through immune mediated mechanisms. Pharmacological analysis indicates that RgIA and Vc1.1 are selective antagonists of α9α10 nAChRs. A recent study also reported that these α9α10 antagonists are also potent GABA-B agonists. In the current study, we were unable to detect RgIA or Vc1.1 binding to or action on cloned GABA-B receptors expressed in HEK cells or Xenopus oocytes. We review the background, findings and implications of use of compounds that act on α9* nAChRs.11* indicates the possible presence of additional subunits.
publishDate 2009
dc.date.none.fl_str_mv 2009-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/79623
McIntosh, J. Michael; Absalom, Nathan; Chebib, Mary; Elgoyhen, Ana Belen; Vincler, Michelle; Alpha9 nicotinic acetylcholine receptors and the treatment of pain; Pergamon-Elsevier Science Ltd; Biochemical Pharmacology; 78; 7; 10-2009; 693-702
0006-2952
CONICET Digital
CONICET
url http://hdl.handle.net/11336/79623
identifier_str_mv McIntosh, J. Michael; Absalom, Nathan; Chebib, Mary; Elgoyhen, Ana Belen; Vincler, Michelle; Alpha9 nicotinic acetylcholine receptors and the treatment of pain; Pergamon-Elsevier Science Ltd; Biochemical Pharmacology; 78; 7; 10-2009; 693-702
0006-2952
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19477168/
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bcp.2009.05.020
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0006295209004298
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Pergamon-Elsevier Science Ltd
publisher.none.fl_str_mv Pergamon-Elsevier Science Ltd
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1867629223425867776
score 12.98848